• Tidak ada hasil yang ditemukan

Supplemental Digital Content 2 ECMO specific data

N/A
N/A
Protected

Academic year: 2024

Membagikan "Supplemental Digital Content 2 ECMO specific data"

Copied!
2
0
0

Teks penuh

(1)

Supplemental Digital Content 2 ECMO specific data

No ECMO mode

Transport distance

(km)

Calculated CI (L/min m2)

Conversion VV to VA

ECMO

complications Days on ECMO Cause of death on ECMO

Death after discharge from ECMO

1 VA 732 2.45 6.1

2† VV IH Day 3 Hypoperfused

cannulated leg 4.8

ECMO withdrawn: Brain- stem

infarctions/comorbidity

3 VA 285 2.33 2.3

4† VV IH Day 8 19.6 ECMO withdrawn:

Herniation

5† VA IH 2.54 2.9 ECMO withdrawn: Cerebral

infarctions/comorbidity

6 VA 23 2.57 9.0

7 VA IH 3.28 VAP 6.6

8 VA IH 2.80 3.9

9 VA 11 2.05 19.1

10 VA 69 2.79 Hypoperfused

cannulated leg 14.8

11 VA 389 1.99 Bleeding

cannulation site 9.0

12 VA 11 2.41 4.0

13† VA 11 2.88 Bleeding

cannulation site 6.9 DAH 4 ds AD

14 VA 397 n/a 6.9

15 VV 432 10.5

16 VA 514 1.78 5.9

17† VV IH Day 2 8.8 DIH 1 d AD

18† VA 343 1.81 2.2 DAH 17 ds AD

19 VV 21 VAP 8.2

20 VA 11 2.27 5.3

21 VA 11 2.52 VAP 4.9

22 VA 348 3.32 6.0

23† VV 622 9.7 DAH 111 ds

AD

24 VA 29 2.76 4.2

25 VV IH 7.7

26† VV 63 Day 15 31.0 DAH 11 ds AD

27 VA 23 2.59 6.5

28† VV 622 Day 5 22.3 ECMO withdrawn: Acute on

chronic fibrotic lung disease

29† VA 314 2.06 3.6

ECMO withdrawn: Severe intracranial

bleeding/Herniation

The table displays mode at commencement of extracorporeal membrane oxygenation

(ECMO), distance to referring hospital, conversions, ECMO complications, length of ECMO

treatment, and cause of death. Data presented as mean (IQR).

(2)

No ECMO mode

Transport distance

(km)

Calculated CI (L/min m2)

Conversion VV to VA

ECMO

complications Days on ECMO Cause of death on ECMO

Death after discharge from ECMO

30† VV 9 Day 2 Intestinal

bleeding 9.7

ECMO withdrawn: Tertiary ACS, intestinal bleeding, circ failure

31† VA 1630 2.64 41.9 DAH 2 d AD

32† VA 22 2.23 19.4

ECMO withdrawn: A. cerebri med infarct, uncunsios, HSV in blood

33 VA 9 2.34 11.6

34 VA IH 2.63 5.9

35 VA 9 1.80 7.1

36 VA 426 1.87 5.3

37† VA 397 2.12 15.7 DAH 1 d AD

VV:VA 10:27

69(16-429) 2.43(2.06-2.71) 60% of VV 21.6% 6.9(5.1-11.0) Survival ECMO: 81.1%

Abbreviations: †=patient deceased, VA=Veno-arterial ECMO, VV=Veno-venous ECMO, IH=In

hospital, CI=VA-ECMO flow per Body surface area, ACS=abdominal compartment syndrome,

d= day(s), AD=After discharge, VAP=Ventilator Associated Pneumonia, DAH=Deceased at Another

Hospital.

Referensi

Dokumen terkait

Assumptions regarding perinatal transmission of human immunodeficiency virus HIV The assumed proportions of women who receive different forms of prophylaxis are based on a 2010

The initial vitronectin concentration was estimated based on the data in Preissner et al.13 and Declerck et al.14 The model was solved with the integration parameters used in our

Unidentified urine metabolites of the PLS-DA models based on overall metabolite patterns associated with autologous blood transfusion in negative neg and positive pos electrospray

S2B, Supplemental Digital Content 1, mice received a single intraperitoneal injection of NOX-D19 20 mg/kg in 220 µl 5% glucose or solvent 5% glucose 23 h post infection and were

A and B, Immunohistochemistry analysis of FPN expression in airway epithelium in lung tissues prepared at 0 hour steady control and 6 hours after infection.. B Quantitative data are

Data were analyzed by repeated measures ANOVA with Greenhouse- Geisser correction for the sphericity assumption on variances, followed by the comparison of all parameters R, Angle,

Supplemental Digital Content 5: Adverse reactions The safety report was yearly prepared with the data provided by Dynamic Solutions CRO as required by Farmacovigilance Department..

PELAGIE cohort N=3421 Planned pregnancies N=2995 181 unplanned pregnancies 245 missing data 39 missing TTP 13 missing fish or shellfish consumption data Available TTP and